Status:
COMPLETED
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
Lead Sponsor:
Eli Lilly and Company
Conditions:
Non-Small-Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
Eligibility Criteria
Inclusion
- Must be at least 18 years old
- Must have been diagnosed with advanced or metastatic non-small cell lung cancer
- Must be able to visit the doctor's office every 28 days for 6 months or longer.
Exclusion
- Pregnant or breastfeeding women
- Have other significant medical problems as determined by your physician
- Are unable to swallow tablets
- Have a history of significant heart disease
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00105092
Start Date
March 1 2005
End Date
February 1 2007
Last Update
May 1 2007
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Tampa, Florida, United States
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Nashville, Tennessee, United States
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Houston, Texas, United States